Ethionamide biomimetic activation and an unprecedented mechanism for its conversion into active and non-active metabolites.

@article{Laborde2016EthionamideBA,
  title={Ethionamide biomimetic activation and an unprecedented mechanism for its conversion into active and non-active metabolites.},
  author={Julie Laborde and C{\'e}line Deraeve and Carine Duhayon and Genevi{\`e}ve Pratviel and Vania Bernardes-G{\'e}nisson},
  journal={Organic \& biomolecular chemistry},
  year={2016},
  volume={14 37},
  pages={
          8848-8858
        }
}
Ethionamide (ETH), a second-line anti-tubercular drug that is regaining a lot of interest due to the increasing cases of drug-resistant tuberculosis, is a pro-drug that requires an enzymatic activation step to become active and to exert its therapeutic effect. The enzyme responsible for ETH bioactivation in Mycobacterium tuberculosis is a monooxygenase (EthA) that uses flavin adenine dinucleotide (FAD) as a cofactor and is NADPH- and O2-dependant to exert its catalytic activity. In this work… 
Xanthates: Metabolism by Flavoprotein-Containing Monooxygenases and Antimycobacterial Activity
TLDR
It is reported here that several xanthates are oxidized by purified EtaA to S-oxide metabolites (perxanthates), which are implicated in the antimycobacterial activity of these compounds.
New insights into ethionamide metabolism: influence of oxidized methionine on its degradation path.
TLDR
It was proved that the presence of oxidized methionine in cells could influence ETH's degradation, leading to the appearance of an inactive metabolite that is detectable by HPLC and mass spectrometry.
Is IQG-607 a Potential Metallodrug or Metallopro-Drug With a Defined Molecular Target in Mycobacterium tuberculosis?
TLDR
MIC measurements andmacrophage infection experiments with a laboratorial strain showed that katG mutation is sufficient to confer resistance to IQG-607 and that the macrophage intracellular environment cannot trigger the self-activation mechanism.
Update of Antitubercular Prodrugs from a Molecular Perspective: Mechanisms of Action, Bioactivation Pathways, and Associated Resistance
TLDR
Identification of the prodrugs targets and a better understanding of their modes of action and also of their activation mechanisms are of crucial importance, as well as the reported resistance related to these mechanisms of activation/action.
Antibacterial Activity of Pharmaceutical-Grade Rose Bengal: An Application of a Synthetic Dye in Antibacterial Therapies
TLDR
Toxicity data obtained through the research programs indicate that HP-RB is feasible as an anti-infective drug for the treatment of skin and soft tissue infections involving multidrug-resistant (MDR) microbial invasion of the skin, and for eradicating biofilms.
Molecular Determinants of Ethionamide Resistance in Clinical Isolates of Mycobacterium tuberculosis
TLDR
Phenotypic methods for testing ethionamide are imperfectly correlated, and the isolates with MIC of 5 mg/L have the intermediate resistance, and a significant proportion of resistant TB cases are susceptible and eligible for ethion chloride treatment.

References

SHOWING 1-10 OF 28 REFERENCES
Selective intracellular accumulation of the major metabolite issued from the activation of the prodrug ethionamide in mycobacteria.
TLDR
The results strongly suggest that ETH* is the active antimycobacterial ethionamide derivative and open new perspectives for the understanding of the mode of action of prodrugs.
Activation of the pro-drug ethionamide is regulated in mycobacteria.
TLDR
New avenues of research relating to ETH activation in mycobacteria are opened up, possibly leading to an improved efficacy of ETH and to the generation of new anti-mycobacterial agents.
Synthesis, oxidation potential and anti–mycobacterial activity of isoniazid and analogues: insights into the molecular isoniazid activation mechanism
TLDR
An activation mechanism for INH and analogues is proposed based on a one-electron oxidation step of the hydrazyl function at the proximal nitrogen followed by a radical transposition to the distal nitrogen, which then induces a b-homolytic cleavage of the C(=O)-N bond to afford diazene and the isonicotinoyl radical species.
A Fast and Efficient Metal‐Mediated Oxidation of Isoniazid and Identification of Isoniazid–NAD(H) Adducts
TLDR
Characterise the InhA inhibitors (named INH–NAD(H) adducts) which are generated, in the presence of the nicotinamide coenzyme NAD+, by oxidation of INH with manganese(III) pyrophosphate, a nonenzymatic and efficient oxidant used to mimic INH activation by the catalase–peroxidase KatG inside M. tuberculosis.
Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis.
TLDR
Synthesis of radiolabeled ETA and an examination of drug metabolites formed by whole cells of Mycobacterium tuberculosis have allowed it to be demonstrated that ETA is activated by S-oxidation before interacting with its cellular target.
The Prodrug Activator EtaA from Mycobacterium tuberculosis Is a Baeyer-Villiger Monooxygenase*
EtaA is a newly identified FAD-containing monooxygenase that is responsible for activation of several thioamide prodrugs in Mycobacterium tuberculosis. It was found that purified EtaA displays a
Flavins as organocatalysts for environmentally benign molecular transformations.
TLDR
One of the fortunate outcomes of this study is the development of an environmentally friendly ("green") method for the "aerobic hydrogenation" of olefins, which is achieved by in situ generation of diimide with the aid of the flavin-catalyzed oxidation of hydrazine under an O(2) atmosphere.
The Antituberculosis Drug Ethionamide Is Activated by a Flavoprotein Monooxygenase*
TLDR
The results establish that the enzyme (EtaA) is an FAD-containing enzyme that oxidizes ETA to the corresponding S-oxide, and is probably responsible, as suggested by the observation of crossover resistance, for the oxidative activation of other thioamide antitubercular drugs.
...
1
2
3
...